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Several reports have been published on the isolation, culture, and identification of mesenchymal stem cells 
(MSCs) from different anatomical regions of the umbilical cord (UC). UC is suitable for standardizing meth-
ods of MSC isolation because it is a uniform source with high MSC numbers. Although the UC is considered 
a medical waste after childbirth, ethical issues for its use must be considered. An increased demand for MSCs 
in regenerative medicine has made scientists prioritize the development of MSC isolation methods. Several 
research groups are attempting to provide a large number of high-quality MSCs. In this study, we present a 
modulated explant/enzyme method (MEEM) to isolate the maximum number of MSCs from the entire UC. 
This method was established for the isolation of MSCs from different anatomical regions of the UC altogether. 
We could retrieve 6 to 10 million MSCs during 8 to 10 days of primary culture. After three passages, we 
could obtain 8–10 × 108 cells in 28–30 days. MSCs isolated by this method express CD73, CD90, CD105, and 
CD44, but they do not express hematopoietic markers CD34 and CD45 or the endothelial marker CD31. The 
genes SOX2, OCT4, and NANOG are expressed in isolated MSCs. The capacity of these MSCs to differentiate 
into adipocytes and osteocytes highlights their application in regenerative medicine. This method is simple, 
reproducible, and cost efficient. Moreover, this method is suitable for the production of a large number of high-
quality MSCs from an UC in less than a month, to be used for cell therapy in an 80-kg person.
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INTRODUCTION
Current research is increasingly focusing on mes-
enchymal stem cells (MSCs). The advantage of MSCs 
in cell therapy is their low immunogenicity. Therefore, 
they can be used as allogeneic cells (27). According to 
the International Society for Cellular Therapy (ISCT), 
different characteristics can be used for the identifica-
tion of MSCs, such as adherence on a cell culture dish; 
expression of CD44, CD105, CD90, and CD73 surface 
markers; and differentiation into different cell lines, 
including adipocytes and osteocytes (12). MSCs can 
be isolated from different tissues, including adipose 
(7), cord blood (5,33), heart (5), lung (17), bone mar-
row (2), central nervous system (29), placenta (21), 
umbilical cord (UC) (28), and amniotic membrane (41) 
tissues. The advantages of MSCs over embryonic stem 
cells are their low immunogenicity, low tumorigenic 
potential, and few associated ethical and legal dilemmas 
(11). However, the low potential of differentiation and 
the variation in MSCs obtained from different tissues 
or even different regions of a tissue pose difficulties in 
standardizing methods for their isolation. MSCs can 
proliferate in large numbers and produce different mol-
ecules such as growth factors and immunomodulators. 
Therefore, they are considered suitable for cell therapy 
applications. In 1976, MSCs were isolated from bone 
marrow for the first time and were comprehensively stud-
ied (15,16). Although MSCs isolated from bone marrow 
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have numerous applications in research and clinical tri-
als, there are some problems in obtaining bone marrow 
samples, such as invasive sampling, limited number of 
donor volunteers, and reduced function of MSCs iso-
lated from old persons. Therefore, researchers have been 
trying to find substitutes for bone marrow. Wharton’s 
jelly, a mucoid tissue within the UC, is a good substitute 
for bone marrow since it is easily and abundantly avail-
able. Because the UC is considered medical waste after 
parturition, no legal issues are imposed. Furthermore, 
sampling and removing this tissue is not painful for 
the mother or child. MSCs isolated from Wharton’s 
jelly easily proliferate and differentiate to different cell 
lines, and they are not tumorigenic (38). These cells 
have characteristics of MSCs, and they also express 
genes specific to embryonic stem cells, such as sex-
determining region Y-box 2 (SOX2), octamer-binding 
transcription factor 4 (OCT4), and NANOG (26). Thus, 
MSCs isolated from the UC have more proliferation and 
differentiation potential than MSCs isolated from bone 
marrow or adipose tissue (14). Furthermore, the other 
advantages of the UC are the number of MSCs present 
and their chromosomal stability (24,40). Owing to the 
unique characteristics of UC-MSCs, there are several 
methods for their isolation and culture; however, there 
is no consensus on a standard method. Enzymatic diges-
tion and explant culture methods are two ways of isolat-
ing MSCs from the UC. Various anatomical regions of 
the UC have different numbers of MSCs. Researchers 
have paid particular attention to two arteries and one 
vein of the UC, which contain MSCs in the subvascu-
lar regions. Wharton’s jelly also contains MSCs (22). 
There are disagreements about the quality of MSCs iso-
lated from different anatomical regions of the UC. Many 
researchers are attempting to find a standard method for 
isolating MSCs of the UC (18). In the present study, 
we introduce a rapid, simple, and effective method for 
isolating MSCs from the entire UC. We aimed at cost-
effective isolation of a large number of MSCs in a short 
time. Once this method is standardized, it can be used in 
clinical applications, research, and cell banking.
MATERIAlS AND METhODS
Obtaining Informed Consent and Collecting UCs
Fifteen UCs were collected just after birth from nor-
mal, full-term newborns. The deliveries were performed 
by a gynecologist at Valiasr Hospital, Tehran University 
of Medical Sciences (TUMS). All experiments were 
approved by the Ethics and Clinical Studies Research 
Committee of TUMS according to Helsinki declaration. 
Informed consents were obtained from all mothers before 
surgery. Each UC was carried in a sterile dish contain-
ing phosphate-buffered saline (PBS; Life Technologies, 
Carlsbad, CA, USA), 100 U/ml penicillin (Sigma-Aldrich, 
St. Louis, MO, USA), and 100 U/ml streptomycin 
(Sigma-Aldrich) at 4°C and was immediately transferred 
to the Pediatric Urology Research Center of TUMS. The 
samples were placed in a refrigerator (4−8°C) for 1 to 
18 h before processing.
Preparation of UCs and Vascular Isolation
The UCs were transferred to a biosafety cabinet II 
and were washed several times with sterilized PBS (Life 
Technologies) to remove traces of blood. Each UC was 
then placed in a 10-cm sterilized dish (Jet Biofil, Elgin, 
IL, USA) and was divided into 10-cm pieces. The blood 
vessels were carefully isolated from each piece of UC 
without any rupture. After isolation, both ends of each 
vessel were closed by a sterilized plastic clamp to pre-
vent any cross contamination of endothelial and blood 
cells with MSCs. In this way, each piece of vessel 
formed a loop. The loops were mildly digested by col-
lagenase type I (Life Technologies) (0.2 mg/ml) for 3 h 
at room temperature with mild shaking. Enzyme activity 
was neutralized by adding 10% fetal bovine serum (FBS; 
Life Technologies) in Dulbecco’s modified Eagle’s 
medium–low glucose (DMEM-LG; Life Technologies). 
The UC tissues were further cut into tiny pieces and 
digested with collagenase type I for 16 h (0.2 mg/ml; 
Life Technologies) Enzyme activity was neutralized by 
adding 10% FBS in DMEM-LG. In order to compare the 
results of those methods with the results of our modu-
lated explant/enzyme method (MEEM), MSCs from 
each UC were isolated according to tissue explant and 
enzymatic digestion methods.
Culture of Total Length of UC by MEEM
After mild digestion (3 h in 0.2 mg/ml collagenase 
type I), vessel loops were placed in T75 flasks (SPL, 
Pocheon-si, South Korea) containing DMEM-LG sup-
plemented with 15% FBS. After partial digestion (16 h 
in 0.2 mg/ml collagenase type I), the digested umbilical 
cord tissues were treated with PBS to decrease the vis-
cosity and then centrifuged for 10 min at 500 × g. After 
removing the supernatant, the tiny partially digested tis-
sues were transferred into the same T75 flasks containing 
the vascular loops. The UC pieces and the vascular loops 
were cultured in DMEM-LG and 15% FBS. Each UC 
was divided into three to six T75 flasks.
Time Taken by Cells to Form 90% Confluent Primary 
Culture in MEEM, Explant, and Enzymatic Methods
The UC tissues were grown in primary culture using 
MEEM, explant, and enzymatic methods in T75 flasks. 
For each of these three methods, the time taken to reach 
90% cell confluency in primary culture was measured 
(Table 1). Obtained MSCs were seeded (1 × 104/well) in 
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24-well plates (Jet Biofil) in triplicate. Time taken to reach 
90% cell confluency was calculated using an inverted 
microscope (TS100; Nikon, Gotenba, Japan). The num-
ber of cells was calculated using Neubauer slides. Cell 
viability was checked by trypan blue (Sigma-Aldrich) 
dye exclusion.
Growth Curve
For calculating the population doubling time (PDT), 
MSCs obtained by MEEM, explant, and enzymatic meth-
ods were plated in 24-well plates (Jet Biofil). The num-
ber of cells in each well was 4 × 104. Cells were counted 
daily in triplicates, and the mean was calculated for each 
method. Any increase in the number of cells was calcu-
lated for 7 consecutive days. Growth curves were plotted 
according to the number of cells. The PDT was calculated 
from the growth curves.
Immunophenotyping of UC-MSCs by Flow Cytometry
During passage 3 at 80–90% cell confluency, the 
medium was removed, and the cells were washed three 
times with warm PBS. They were then treated with 
0.25% trypsin–EDTA (Life Technologies) for 3 min. The 
enzyme was neutralized by adding complete medium 
(DMEM-LG) and 15% FBS, and the cell suspension 
was centrifuged at 500 × g for 5 min. Cell viability was 
calculated by the trypan blue (Sigma-Aldrich) dye exclu-
sion method. Next, the harvested cells were stained with 
CD105 (Cat: ab44967, 3 µg/106 cells; Abcam, Milton, 
Cambridge, UK), CD90 (Cat: ab23894, 1 µg/106 cells; 
Abcam), CD73 (Cat: ab54217, 2 µg/106 cells; Abcam), 
CD44 (Cat: ab6124, 1 µg/106 cells; Abcam), CD45 (Cat: 
ab10559, 3 µg/106 cells; Abcam), HLADR (Cat: ab8085, 
0.01 µg/106 cells; Abcam), CD31 (Cat: ab9498, 50 µl/106 
cells; Abcam), and CD34 (Cat: ab8536, 20 µl/106 cells; 
Abcam) anti-human-specific monoclonal antibodies. Neg-
a tive control staining was performed by incubating cells 
with an identical concentration (as the concentration of 
the samples) of FITC- and PE-conjugated mouse IgG 
isotype antibodies. After 20 min of incubation at room 
temperature in the dark, stained cells were resuspended in 
400 µl PBS and analyzed by CyFlow® Space flow cytom-
eter (Partec, Münster, Germany). Histograms were gener-
ated based on computed results using Windows™-based 
flow cytometry software.
Evaluation of OCT3/4, SOX2, and NANOG Gene 
Expression by Reverse Transcription Polymerase 
Chain Reaction (PCR)
MSCs were collected in RLT buffer provided with 
RNeasy Plus Kit (Qiagen, Frederick, MD, USA) and 
stored at −80°C. Total RNA was extracted from MSCs 
using the RNeasy Plus Kit, and cDNA was generated. 
The PCR analysis was performed in all three meth-
ods using hot start Taq polymerase and a final volume 
of 25 µl per reaction. PCR was performed in a thermal 
cycler (Eppendorf Mastercycler Personal, Hamburg, 
Germany) to amplify target DNA according to the fol-
lowing protocol: initial denaturation at 95°C for 5 min, 
followed by 40 cycles of denaturation at 95°C for 30 s, 
annealing at 61°C for 30 s, and extension at 72°C for 
60 s. The reaction was completed with a final extension at 
72°C for 5 min. The success of PCR was tested with aga-
rose (Sigma-Aldrich) gel electrophoresis, SYBER safe 
(Cat: S33102; Invitrogen, Waltham, MA, USA) DNA 
gel staining, and gel documentation (Gel Doc System; 
Nanolytik® NanoGel, Düsseldorf, Germany). The house-
keeping gene, GAPDH was used as a positive PCR con-
trol. The gene-specific primers and size of PCR products 
are shown in Table 2.
Table 2. Gene-Specific Primers, Size of Products, and NCBI Reference Sequence Numbers
Gene Forward Primer (5¢–3¢) Reverse Primer (5¢–3¢) Product Size
NCBI Reference 
Sequence Number
GAPDH GTTCCAATATGATTCCACCC TGAGTCCTTCCACGATACC 400 M33197.1
NANOG TGCCTCACACGGAGACTG GCTATTCTTCGGCCAGTT 353 NM_024865.2
OCT3/4 CGACCATCTGCCGCTTTGAG CCCCCTGTCCCCCATTCCTA 543 NM_203289.4
SOX2 ATGCACCGCTACGACGTGA CTTTTGCACCCCTCCCATTTT 437 NM_003106.2
Table 1. Time (Days) Taken to Reach 90% Cell Confluency for 15 Umbilical Cord Samples
Number of Days
MEEM 12 10 11 9 9 10 8 9 8 11 7 8 10 9 7
Enzyme method 22 – 20 18 25 – 19 23 21 20 – 18 23 – 19
Explant method 21 19 – 18 – – 17 16 – 19 29 – 20 – 21
MEEM, modulated explant/enzyme method. Average time until desired cell confluency attained was 9.2 days for MEEM, 20.7 
days for explant method, and 20.1 days for enzyme method. The success rates were 100% (15/15), 60% (9/15), and 73.3% (11/15), 
respectively.
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Differentiation of UC-MSCs to Adipocytes
In all three methods, MSCs after the third passage 
were seeded (2 × 104 cells /well) in six-well plates (Jet 
Biofil) with complete medium (DMEM LG + 15% FBS). 
In 90% cell confluency, the complete medium was 
substituted by adipogenic medium containing 0.5 µM 
isobutyl xanthine (Sigma-Aldrich), 50 µM indometha-
cin (Sigma-Aldrich), 2.0 µM insulin (Sigma-Aldrich), 
0.5 µM dexamethasone (Sigma-Aldrich), and 10% FBS. 
The medium was changed every 3 days. After 24 days, 
the cells were fixed by 4% paraformaldehyde (Sigma-
Aldrich), washed with PBS, and stained with 0.3% Oil 
red O (Sigma-Aldrich).
Differentiation of UC-MSCs to Osteoblasts
In all three methods, MSCs after the third passage were 
seeded (2 × 104 cells/well) in six-well plates (Jet Biofil) 
with complete medium (DMEM LG + 15% FBS). In 80% 
cell confluency, the complete medium was substituted by 
osteogenic medium, containing 0.1 µM dexamethasone, 
0.2 µM ascorbic acid 2-phosphate (Sigma-Aldrich), 10 mM 
glycerol 2-phosphate (Sigma-Aldrich), and 10% FBS. The 
medium was changed every 3 days. After 24 days, the cells 
were fixed using 4% paraformaldehyde (Sigma-Aldrich), 
washed with PBS, and stained with Alizarin red S (Cat: 
BI1009; Fluka, Buchs SG, Switzerland).
RESUlTS
Isolation and Culture of UC-MSCs by MEEM, 
Explant, and Enzymatic Methods
Umbilical cord primary cultures (N = 15) were obtained 
by MEEM, explant, and enzymatic methods. Based on 
calculated PDT and time to reach >90% cell confluency, 
the average of harvested MSCs per 10-cm piece of UC 
were estimated to be 550,000, 150,000, and 280,000 in 
MEEM, explant, and enzymatic methods, respectively. 
Using trypan blue dye exclusion, the mean percentages 
of viable cells were 90%, 95%, and 78%, respectively. 
Inverted microscopy revealed fibroblast-like morphology 
after 16 h for MEEM (Fig. 1A), after 48 h for the enzy-
matic method (Fig. 1B), and after 72 h for the explant 
method (Fig. 1C).
Time Taken to Reach 90% Cell Confluency 
and Success Rate in Primary Cultures
For all samples, the time required to reach 90% con-
fluence was determined. The results are shown in Table 2. 
On an average, cells took 9.2, 20.7, and 20.1 days, respec-
tively, to reach 90% confluency with MEEM, explant, 
and enzymatic methods. The respective success rates 
were 100% (15/15), 60% (9/15), and 73.3% (11/15).
Average Cell Counts and Culture Durations 
in Different Stages of MEEM Method
We isolated almost 30,000,000 MSCs from each UC 
in primary culture during the first 10 days (five T75 flasks 
each with 6,000,000 MSCs in 90% confluency). They 
were then subcultured every 6 days in the ratio 1 to 3. 
We had approximately 90,000,000 MSCs in day 16 (first 
passage at 90% confluency), 270,000,000 MSCs in day 
23 (second passage at 90% confluency), and 810,000,000 
MSCs in day 29 (third passage at the 90% confluency). 
We worked on 15 UCs during this project, and results of 
all the samples confirmed each other.
Growth Curve and PDT Estimation
Growth curve of UC-MSCs at passage 3 were plotted. 
PDT did not differ across MEEM, explant, or enzymatic 
methods (Fig. 2A). The PDT for the entire UC-derived 
MSCs was 36 h (Fig. 2B).
Cell Surface Antigen Expression Profile of 
UC-MSCs by Flow Cytometry
UC-MSCs isolated by MEEM were positive for sur-
face MSC antigens (CD105, CD90, CD73, and CD44) 
and negative for hematopoietic stem cell markers (CD45, 
CD34). These cells did not show expression of CD31 
(endothelial cell marker) or HLADR (Fig. 3). The immu-
nophenotype of total UC-MSCs obtained by MEEM was 
similar to those obtained by explant and enzymatic meth-
ods, which is in agreement with the findings of one study 
in 2006 (12) (data not shown).
Gene Expression Assessment by RT-PCR
To demonstrate the expression of pluripotent genes 
NANOG (Fig. 4A), SOX2 (Fig. 4B), and OCT4 (Fig. 4C) 
Figure 1. Fibroblast-like morphology in umbilical cord mesenchymal stem cell primary culture. (A) Modulated explant/enzyme method 
(MEEM) after 16 h. (B) Enzymatic method after 48 h. (C) Explant method after 72 h. Original magnification: ×4. Scale bars: 100 µm.
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RT-PCR was performed on UC-MSCs obtained by MEEM, 
explant, and enzymatic methods (Fig. 4).
Cell Culture Morphology Assessment of MEEM 
by Inverted Microscopy
After 16 h of MEEM culture, fibroblast-like attached 
cells appeared (Fig. 5A). After 48–72 h, small hetero-
geneous cell colonies were seen (Fig. 5B). The cells 
were fibroblast-like, flattened, and polygonal, with high 
nuclear/cytoplasm ratio. Seventy-two hours after the ini-
tiation of culture, vascular loops were removed carefully 
to avoid rupture. The cells and colonies increased mark-
edly after 5 days (Fig. 5C), and flasks were confluent 
by about day 10 (Fig. 5D). DMEM-LG medium (2 ml) 
supplemented with 10% FBS was added every other day 
during MEEM culture of UC tissue without removing the 
previous medium.
Evaluation of Living Cells in Different Passages
Using trypan blue dye exclusion technique, the per-
centage of living cells obtained by MEEM for different 
passages was estimated to be about 97%.
Mesodermal Lineage Differentiation Potential 
of UC-MSCs Derived by MEEM
When placed in the specific differentiation media for 
24 days, UC-MSCs obtained by MEEM, explant, and 
enzyme methods differentiated into osteocytes and adi-
pocytes. No deposition of minerals or formation of lipid 
droplets was observed in the absence of differentiation 
medium (Fig. 6A–C). Deposition of calcium and miner-
alization of cells was observed by inverted microscopy 
as the appearance of red color after Alizarin red S stain-
ing (Fig. 6D, E, and F). Formation of lipid droplets and 
accumulation of lipid vacuoles was observed by inverted 
microscopy as the appearance of red color after Oil red O 
staining (Fig. 6G–I).
DISCUSSION
The MEEM method, we developed in this study, helped 
us isolate a larger number of MSCs from various anatomi-
cal regions of the UC in a shorter time than that required for 
enzymatic digestion and explant culture methods. Besides 
the advantages in ease of operation, MSC yield is high 
using this method. The isolated cells have an MSC-like 
Figure 2. Growth kinetics of umbilical cord mesenchymal stem cells. Umbilical cord mesenchymal stem cells (40,000 cells per 
well) were plated in 24-well plates. Cells were counted in triplicate every day, and the mean number of cells was calculated for each 
method. (A) Triplicate MEEM (solid line), explant (dotted line), and enzymatic (dashed line) cultures were harvested for trypan blue 
dye exclusion cell count every day. (B) The population doubling time was calculated from the modulated explant/enzyme method 
(MEEM) curves.
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morphology, express MSC-specific markers, and can dif-
ferentiate into adipocytes and osteocytes.
MSCs can be isolated from different types of tissues 
(8,19) and have the potential for renewal and differentiating 
into different types of cells. Therefore, they are considered 
useful for various clinical applications. There is a need to 
review and optimize current techniques for isolating MSCs 
from the UC (9). In addition to the reproducibility of the 
technique, the morphology and phenotype of isolated cells 
should be maintained in different passages (26). Some 
groups have tried to optimize the use of enzyme methods. 
Improvement in the quality of the isolated cells among 
these attempts have been reported (18,35). The advantages 
of our study over others include isolation of larger number 
of MSCs from umbilical cord to shorten the length of the 
enzymatic and explant processes. Based on the evidence, 
MSCs isolated from different regions of the UC do not 
show similarities in number, differentiation, and prolifera-
tion (22,36). This underscores the importance of using the 
entire UC in isolating MSCs, which have uniform potential 
for proliferation and differentiation.
Umbilical cord can be considered biological waste. 
Hence, there are only a few minor ethical issues associated 
with the use of umbilical cord in regenerative medicine. 
The UC-MSCs have similar characteristics to embryonic 
stem cells because they are formed in the early stages of 
embryonic development (39). Although UC-MSCs are 
considered to be adult stem cells, the potential for differ-
entiation is greater than that of MSCs derived from other 
sources (31). Owing to the above-mentioned features, 
researchers have tended to isolate MSCs from the umbili-
cal cord to be used in regenerative medicine. Thus far, no 
standard isolation method for UC-MSCs is available. It 
has been reported that differences in isolating and culture 
methods can lead to differences in pluripotent potential 
and gene expression in cells (25). In addition, genetic 
and epigenetic changes of obtained cells can affect their 
clinical uses due to loss of plasticity (32). It should be 
noted that the expression of cell surface markers is influ-
enced by factors secreted by accessory cells in primary 
culture (10). At present, there are enzymatic and tissue 
explant methods for isolating UC-MSCs. Cell yields by 
the explant method are low, and the enzymatic method is 
mostly variable, with occasional instances of cells with 
damaged membranes (37). In this study, we used a combi-
nation of two conventional protocols: tissue explant and 
Figure 4. Gene expression by RT-PCR analysis of the umbilical cord-derived mesenchymal stem cells (UC-MSCs) obtained using 
modulated explant/enzyme method (MEEM), explant (EXP), and enzymatic (ENZ) methods. UC-MSCs express markers of embry-
onic stem cell transcription factors such as NANOG (A), SOX2 (B), and OCT4 (C). A 100-bp DNA ladder (Lad) was used as the DNA 
marker. A lymphoblastoid cell line was used as the negative control (NTC). An embryonic cell line (ESC) was used as the positive 
control (PTC).
Figure 5. Assessment cell culture morphology in MEEM by inverted microscopy. (A) After 16 h, (B) after 48–72 h, (C) after 5 days, 
(D) after 10 days. Scale bars: 100 µm.
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enzymatic method (37). Characteristics of cells obtained 
by MEEM were compared with those obtained by con-
ventional enzymatic and explant methods. The aim of 
this investigation was to introduce an efficient and repro-
ducible method for isolating UC-MSCs. It seems that 
standard features of MEEM are higher than that of con-
ventional methods.
We are the first to have cultured different parts of the 
UC, such as subvascular region, Wharton’s jelly, and 
the subepithelial layer simultaneously using MEEM. 
We found that simultaneous culture of different regions 
of UC using MEEM accelerates the process of attain-
ing desired cell confluency in primary culture. We did 
not observe any difference in the time taken to reach cell 
Figure 6. Osteogenic and adipogenic differentiation of UC-MSCs derived using the modulated explant/enzyme method (MEEM), 
explant (EXP), and enzymatic (ENZ) methods. (A, B, and C) Control; without the use of differentiation media. (D, E, and F) Alizarin 
red S staining after 24 days in osteogenic differentiation medium. (G, H, and I) Oil red O staining after 24 days in adipogenic dif-
ferentiation medium. Scale bars: 50 µm.
confluency after primary cultures using different meth-
ods. We believe the large quantities of cells obtained by 
MEEM in comparison with enzymatic and explant meth-
ods is one important cause of reduction in time to reach 
confluency in primary culture. The estimated number of 
isolated cells from 10-cm pieces of the UC using MEEM 
was about twice that obtained using the enzymatic 
method and four times than that obtained using the tissue 
explant method. Cell quality was the same for MEEM 
and explant methods, but cell quality for the enzymatic 
method was lower owing to membrane damage. The use 
of collagenase combined with trypsin and hyaluronidase 
can damage cell membranes, which reduces strength of 
cell adhesion and growth rate (6).
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Wharton’s jelly contains insoluble collagen, hyaluronic 
acid, and sulfated glycosaminoglycans around MSCs, all 
of which reduce the migration of cells from the tissues to 
flask surfaces. Using enzymes to dissolve these agents can 
facilitate the entry of cells into culture dishes. Different 
enzymes such as collagenase 1, 2, and 4, trypsin, and 
hyaluronidase were used alone or in combination. MSCs 
are very sensitive to trypsin, and other enzymes have 
destructive side effects (42). In MEEM, the tissues were 
finely sliced, and then type 1 collagenase was used for 
mild digestion of the entire UC. Before full digestion of 
UC tissues, enzyme activity was neutralized using com-
plete medium. The entry of cells from mildly digested 
tiny tissues to the flask surface was facilitated by MEEM. 
Because of mild digestion, cell damage was minimal, 
and therefore cells had high adhesion strength and good 
growth potential. Observation of fibroblast-like cells after 
only 16 h indicates timely removal of enzymes and no 
damage to the cells. Owing to the comparable age of new-
borns, there is no considerable difference in UC-MSCs 
derived from different UCs. Thus, MEEM can be intro-
duced as a standard method for isolating UC-MSCs. In the 
tissue explant method, the cells appeared on the surface 
of flasks very late due to low rate of release of cells. In 
MEEM, the rate of release of cells is higher, and the num-
ber of primary isolated cells is greater than that obtained 
by other methods. Furthermore, with regard to cell adhe-
sion strength, expression of MSC surface markers, and 
mesodermal differentiation potential, the quality of the 
MSCs isolated was adequate. There were no differences 
in cell morphology between MSCs obtained by MEEM 
and conventional methods at passage 3. The isolation 
success rate was 100% in MEEM versus 73% in the enzy-
matic method and 60% in the explant method; this can be 
ascribed to the simplicity and reproducibility of MEEM. 
Application of MSCs in regenerative medicine requires a 
large number of high-quality cells. One of the advantages 
of MEEM is obtaining 8 × 108 ± 1.5 × 107 cells in less than 
a month. Considering the fact that the average number 
of cells required for bone marrow transplantation clinical 
trials is 1–2 × 106 MSCs per kg body weight (4), the cells 
obtained by MEEM during a month is sufficient for use 
in a patient weighing 80 kg.
Availability of MSC banks is one of the most chal-
lenging aspects in regenerative medicine. Assessment of 
growth kinetics of UC-MSCs, as well as existing MSC 
surface markers (CD90, CD 70, CD44, and CD 105), lack 
of hematopoietic (CD34, CD45) and endothelial (CD34) 
markers, and their multilineage differentiation potential, 
indicated that suitable and efficient cells were isolated 
using MEEM. Because growth factors are not needed 
for this method, the operational cost is reduced. Another 
advantage of our method is the easy availability of tissues 
since biological waste is being utilized.
Because of immunomodulatory properties of MSCs, 
their allogeneic use as universal donor cells is being con-
sidered (23). Some studies have shown that MSCs can be 
used for allogeneic purposes. For this, the use of serum 
(e.g., FBS) remains a drawback in our study. Some studies 
have recommended the use of autologous serum instead 
of FBS (13). However, we did not consider this in our 
present study. The increase in contact among MSCs (20) 
and the presence of autocrine and paracrine growth factors 
from different accessory cells (3) can accelerate achieve-
ment of cell confluency in primary culture in MEEM. 
Some researchers believe that homogeneous cells isolated 
from specific parts of the UC are most useful in regenera-
tive medicine (30). We postulate that a large number of 
heterogeneous MSC populations obtained from different 
parts of the UC by MEEM can increase secretion of vari-
ous relevant factors that leads to better proliferation and 
differentiation of MSCs. However, this theory warrants 
future research. The PDT of MSCs obtained by MEEM 
(36 h) is shorter than that of MSCs obtained from bone 
marrow (4 days) in previous studies (1). Because of this, 
there is less of a risk of chromosomal changes and cell 
abnormalities in these cells (34). In view of the above-
mentioned issues, we propose the use of MEEM as an 
efficient and simple method for the standardization of 
UC-MSC isolation.
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